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Running head: Limits of normal values for calprotectin 
  
Normal Values for Calprotectin in Stool Samples from the Population-based 
Longitudinal Born into Life Study 
Fecal calprotectin is a protein used as a diagnostic marker for 
inflammatory bowel diseases. We determined upper limits for normal 
calprotectin values for neonatal, 6, 12 and 24 months old children using a 
turbidimetric immunoassay in a cohort of Swedish children. The 
advantage of the method is that, opposite to previously used ELISA 
method, it enables measuring single samples, and thus, shortens the 
analysis times significantly. There were 72 samples (41.7 % female) 
collected neonatally, 63 samples (34.9 % female) at 6 months, 60 samples 
(40.0 % female) at 12 months and 51 samples (43.1 % female) at 24 
months. The upper limits for normal values were 233, 615, 136 and 57 µg 
mg-1 for infants aged 0, 6, 12 and 24 months, respectively. 
Keywords: calprotectin, turbidimetric immunoassay, normal values, 
inflammatory bowel disease, abdominal pain 
 
Introduction 
Abdominal pain is one of the most common causes for seeking medical help during 
childhood and is reported to affect 10% to 20% of schoolchildren at an extent that 
interferes with normal daily activity [1, 2]. Abdominal pain and diarrhea are both 
frequently observed in functional gastrointestinal disorders in children, but it may also 
be the first sign of an inflammatory bowel disease (IBD), which has become more 
  
common among children during the last decades [3, 4]. For long, histopathological 
analysis of biopsies taken during endoscopy were considered the gold standard for 
diagnosing IBD, but as this is an invasive and costly procedure, especially with pediatric 
patients, non-invasive diagnostic tools are sought. New promising markers for 
diagnostic purposes have been suggested, including measurement of the inflammatory 
marker calprotectin, which can be analyzed in fecal samples. While fecal calprotectin 
alone is not sufficient for the initial diagnosis of IBD, it is now considered a reliable 
marker for active IBD in adults [5] and has been suggested to replace biopsies to 
predict early relapse of IBD [6].  It has also recently been suggested for the triage of 
pediatric patients with symptoms suggestive of IBD [7] and can be used as a rule-out 
test for IBD [8]. 
Further, detecting abnormal calprotectin levels in infancy could also be used for other 
diagnostic purposes. For example, high calprotectin values have been linked to the 
development of other immune-mediated diseases, such as atopic dermatitis and 
asthma [9]. Further, higher fecal calprotectin levels have been found in children with 
bacterial gastroenteritis compared to children with viral disease [10].  
Calprotectin is a calcium and zinc-binding protein consisting of two heavy and one light 
polypeptide chains. It is abundant in neutrophils, where it can constitute up to 60 % of 
the total cytostolic protein content [11], but it is also present in monocytes and 
macrophages [12]. The protein can be measured in feces, plasma, and other body 
fluids. In feces it has a homogeneous distribution and is stable for up to 7 days at room 
temperature [13], making it an ideal diagnostic marker. However, constraints related 
to sample analysis have hampered the use of calprotectin, as samples were run in 
batches in 96 well plates using enzyme linked immunosorbent assay (ELISA) and filling 
  
the batch can take a long time. A new method based on particle enhanced 
turbidimetric immunoassay (PETIA), is available, allowing rapid identification of 
calprotectin in single fecal samples, enabling fast analysis [14]. The results obtained 
with this test are comparable to the previously used ELISA method [14]. 
However, in order to use fecal calprotectin in clinical practice, it is essential to 
know the upper limit of normal variation among healthy individuals. Such normal 
values have not been established for the turbidimetric immunoassay. Here we report 
upper limits for normal values of calprotectin in feces based on a cohort of infants 
whose calprotectin levels were measured at birth and at the age of 6, 12 and 24 
months. 
 
Materials and Methods 
The Born into Life Study 
The infants included into this study participated in the Born into Life study (Smew et 
al., submitted), which is a longitudinal cohort study consisting of two cohorts – one of 
mothers, and the other of their children. The mothers were originally recruited into a 
larger prospective cohort study LifeGene [15], which consists of index people between 
18 to 45 years of age. Female study participants in LifeGene who became pregnant 
were recruited into Born into Life and answered questionnaires regarding pregnancy, 
health status and lifestyle at baseline and twice during pregnancy. After gaining 
parental informed consent, the children were included in the birth cohort upon 
delivery and all were delivered at the same clinic. Only healthy, full term infants were 
included in the study. These children were followed with parental questionnaires and 
biological samples were collected at birth and at 6, 12 and 24 months of age (Table 1). 
  
The health status of the children in the cohort represents well the general population 
of young children in Sweden in regards to occurrence of food allergies [16] and eczema 
[17], as well as for antibiotics use[18]. Also the frequency of hospital visits reflects the 
general population of young children in Sweden [19]. [Table 1 near here] 
 
Samples 
Fecal samples were collected at home by the parents from the child’s diaper following 
a standardized protocol the day before visit to the test center, except for the neonatal 
fecal sample which was collected in conjunction with the routine health check-up 2-4 
days after birth. Samples were kept in a freezer and transported to the test center in a 
Cool Transport Container from Sarstedt in frozen condition.  Frozen samples were 
thawed, weighed and calprotectin was extracted according to manufacturer´s 
instructions (BÜHLMANN, Schönenbuch, Switzerland). Ethical approval was granted by 
the Regional Ethics Review Board in Stockholm, Sweden (reference number 2011/192-
31/2, 2011/1127-31/3 and 2014/1081-32 with amendments) and complied with the 
World Medical Association Declaration of Helsinki regarding ethical conduct of 
research. All parents gave informed written consent.  
 
Fecal Calprotectin Assay 
Fecal calprotectin was analyzed with fCal Turbo reagent (BÜHLMANN) on a Mindray™ 
BS-380 analyzer (Mindray Medical International, Shenzhen, China). The fCal 
Turboreagent kit contains Reaction Buffer (R1) and Immunoparticles (R2) and the total 
assay time was 10 min. The total coefficient of variation (CV) for the method was 1.9% 
at 248 µg/g and 0.6% at 1392 µg/g. The fecal calprotectin PETIA shows a good 
  
agreement with the Bühlmann ELISA [14], which in external quality assurance 
programs belongs to a group of manufacturers that has a calibration above the median 
in quality assurance programs [20]. 
 
 
Statistical Analyses 
As the reliable detection limit for calprotectin with the turbidimetric method is around 
5 µg g-1, all values below this, including zeroes, were changed to 0.01. We considered 
95 % reference intervals as normal concentrations, but since values of fecal 
calprotectin that are below detection limit are considered normal, only upper limits 
are reported together with 90% confidence intervals by bootstrap estimation utilizing 
the R-package, referenceIntervals (http://CRAN.R-
project.org/package=referenceIntervals). Outliers were detected using Horn´s method 
[21]. Correlation in calprotectin concentration across time was tested using Spearman 
correlation and the impact of gender to calprotectin levels was tested with t-test. The 
variation among age groups was tested using Kruskal-Wallis one-way analysis of 
variance with posthoc test after Nemenyi using R-Package PMCMR (http://CRAN.R-
project.org/package=PMCMR). The results were considered significant at P < 0.05. All 
calculations were performed using R (http://www.Rproject.org). 
 
Results 
The data include 246 evaluations for 84 individuals across 4 different time points. 
There were 72 samples (41.7 % female) taken neonatally, 63 samples (34.9 % female) 
at 6 months, 60 samples (40.0 % female) at 12 months and 51 samples (43.1 % female) 
  
at 24 months. The values decreased over time with the highest concentrations being 
found at 0 and 6 months, respectively (Figure 1). There was no difference between 
boys and girls and no correlation was found within individuals over time. The upper 
limits for normal values for each time point are presented in Table 2. [Table 2 and 
Figure 1 near here] 
 
Discussion 
Our main purpose of the study was to set upper limits for normal variation in fecal 
calprotectin values during the two first years of life, enabling the use of PETIA as a 
diagnostic tool. These results confirm that the values are very high in newborns [22, 
23], but then decrease fast, apparently stabilizing already at the age of one year.  
There was no trend within individuals, and variation in levels between different ages 
more likely reflects changes in other factors, such as introduction of solid food or mild 
gastrointestinal problems.   
In order to decide if a patient´s test values are decreased, normal or elevated, it 
is important to have appropriate reference values against which the results can be 
evaluated. Most reference values have been based on healthy adults in the 20-50 year 
age range and lack of pediatric upper limits for the normal values has restricted the 
use of fecal calprotectin in children. There is evidence that also dietary factors and the 
bacterial gut flora may influence the levels of inflammatory markers in feces [24-27]. 
Both diet and the frequency of gastrointestinal infections vary between countries [28], 
thus, it is important that the reference material is similar to the patient population that 
the assay will be used for. Here, the pediatric study population was recruited in 
  
Sweden and is considered representative for Caucasians living in the northern part of 
Europe. 
The main application for fecal calprotectin in adults is to distinguish between 
irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). As an 
inexpensive noninvasive assay fecal calprotectin can be used more frequently, allowing 
a closer treatment monitoring than with colonoscopy. It can thus be used to monitor 
the effects of different diets on the inflammatory activity [20]. In children, there is also 
another possible application. A previous study has indicated that fecal calprotectin 
could be used as a tool for distinguishing between viral and bacterial gastroenteritis 
with a specificity of 88.9%, and specificity of 76.0% for a cut-off of 710 mg/l [10]. 
Another large study found strong associations of calprotectin with viral/bacterial 
diagnosis and also found that the levels of calprotectin were associated with more 
severe disease in children with more severe gastroenteritis in both the bacterial and 
viral group separately [29]. However, a third study in 50 children showed no additional 
benefit of measuring fecal calprotectin above CRP measurement for the discrimination 
of viral to bacterial gastroenteritis [30]. Further, larger validation studies are needed 
on this issue, and if shown predictive, rapid determination of fecal calprotectin with 
normal values would be needed before implementation into the clinical setting.  
The limitation of this study is that the number of participants was low. This could 
impact, for example, the variation within values. For example, one of the values at six 
months was very high (> 1000 µg mg-1), but due to the small sample size we do not 
know whether such high values are regularly detected in young healthy infants. 
To conclude, determining the upper limits for normal values enables the use of 
the turbidimetric immunoassay as a diagnostic tool for gastrointestinal disorders in 
  
children under 2 years, facilitating fast and cost efficient monitoring of gastric 
inflammation. 
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Table 1. Summary of the health questionnaire data for the cohort for the 6, 12 and 24 
months check-up. 
 
6 months 12 months 24 months 
number of respondents/total 53/63 56/60 45/51 
    Did your child ever have any of the following… 
Abnormal head circumference 4% 
  Delayed mental development 0% 
  Delayed motoric development 0% 
  Hearing problem 0% 
  Heart disease 0% 
  Hip problem 0% 
  RS-virus infection 0% 
  Testicles not in scrotum 0% 
  Too large weight gain 0% 
  Too small weight gain 13% 
  Visual impairment 0% 
  
    Did your child ever have… 
   Asthma 
 
2% 4% 
Colic 
 
4% 0% 
Common Cold 
 
93% 98% 
Conjunctivitis 
 
13% 27% 
Diarrhea 
 
54% 44% 
Eczema 
 
25% 20% 
Pinworm 
 
0% 2% 
Fever seizures 
 
2% 2% 
Food allergy 
 
4% 7% 
Hives 
 
7% 13% 
Otitis 
 
11% 16% 
Pneumonia 
 
0% 0% 
False Croup 
 
4% 4% 
Tonsillitis 
 
4% 4% 
Urinary tract infection 
 
2% 2% 
    Did your child ever… 
   Use antibiotics 13% 18% 29% 
Visit a hospital for disease 30% 43% 40% 
 
 
 
  
 
Table 2. Upper limits for normal values for calprotectin in feces of neonates, 6 and 12 
month-old infants and 2-year old children determined as 95 % reference intervals with 
90 % confidence intervals, and their median values. 
Age (months) N (number of excl. 
outliers) 
Upper limit (µg g-1; 90% 
confidence interval) 
Median (µg g-1) 
0 71 (2) 324 (274 – 381) 67 
 6 63 (0) 615 (189 – 1057) 31 
12 54 (6) 136 (119 – 179) 19 
24 40 (11) 57 (57 – 64) 17 
 
Figure 1. Boxplot of fecal calprotectin concentrations within each of the age classes. 
Letters illustrate significant differences between groups. One high value (1056 µg g-1) 
in age group 6 months was excluded from the figure. 
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